Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood thinner may stop early cirrhosis from turning deadly — a major trial puts it to the test

NCT ID NCT07726693

Not yet recruiting Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

Liver disease is the only major cause of death on the rise, and once cirrhosis develops, no proven medications exist to help people live longer. This trial tests whether apixaban, a blood thinner already used for clots, can prevent early-stage cirrhosis from progressing to a dangerous 'decompensated' state that causes severe symptoms and shortens life. Over 1,100 participants with compensated cirrhosis will take either apixaban or a placebo for up to four years to see if the drug delays or prevents liver-related hospitalizations and death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a blood-thinning drug called apixaban (2.5 mg twice daily)
What this could lead to
If it works, this could offer the first medication proven to help people with early cirrhosis live longer without severe liver complications.
What could go wrong
This is a large trial, but earlier smaller studies were not conclusive. Apixaban increases bleeding risk, which could be dangerous in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER CIRRHOSIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.